Evaluation of Children with Secondary Osteoporosis: A Single-center Experience Sekonder Osteoporoz Tanılı Çocukların Değerlendirilmesi: Tek Merkez Deneyimi


Creative Commons License

Abalı Z. Y., BAŞ F., Poyrazoğlu Ş., Öztürk A. P., Bundak R., Darendeliler F.

Medical Journal of Bakirkoy, cilt.19, sa.1, ss.51-56, 2023 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 1
  • Basım Tarihi: 2023
  • Doi Numarası: 10.4274/bmj.galenos.2023.2023.1-12
  • Dergi Adı: Medical Journal of Bakirkoy
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL
  • Sayfa Sayıları: ss.51-56
  • Anahtar Kelimeler: Bisphosphonates, secondary osteoporosis, pediatric endocrinology
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: Children with chronic diseases are at a risk of inadequate bone mineralization due to the effects of the primary disease and/or treatment. The aim of this study was to evaluate the clinical characteristics and treatment responses of patients with secondary osteoporosis. Methods: Forty-four patients with chronic diseases who had bone mineral density (BMD) Z-score of ≤-2.0 on the dual-energy X-ray absorptiometry (DXA) were included. Results: Age at diagnosis of osteoporosis was 9.2±4.9 years (1.4-17.7 years). Chronic disease groups were defined as gastrointestinal (29.5%), neurological (22.7%), hematologic (18.2%), inborn errors in metabolism (11.4%), rheumatologic (9.1%), and renal (9.1%). The rate of receiving steroid treatment was 63.6%. DXA Z-score was -2.8±0.9. The fracture frequency in the long bones was 20.5%. Bisphosphonate (BP) treatment was given in 34.1% (n=15) of the patients. BP was the most commonly used in neurological diseases (50%). A significant difference was found between the initial and final DXA Z-scores in BP patients (-3.3±1.0 and -2.4±0.9; p=0.004). Conclusion: In our study, a heterogeneous group of chronic systemic diseases was evaluated, and BP treatment provided a significant improvement in BMD. Further prospective studies are still required in which clinical and radiological improvements are evaluated in large groups of patients.